|
|
|
|
|
|
|
|
|
|
|
07.08.26 - 22:36
|
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
WILMINGTON, Del.--(BUSINESS WIRE)--$INCY--Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company's common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company's common stock to 24 new employees. The awards were made under the Company's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company's board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Each RSU vests as to 25% of the shares subject to the RSU on each of the first four anniversaries of the vesting commencement date, subject to the employee's continued service with the Company on each such date. The stock options have an exercise price of $118.43 per share, which is equal to the closing price ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.07.26 - 14:18
|
Incyte Corporation Profit Rises In Q2 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) announced earnings for its second quarter that Increases, from the same period last yearThe company's bottom line came in at $585.605 million, or $......
|
|
|
|
|
28.07.26 - 13:03
|
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
|
|
|
Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025
Total net sales, excluding the one-time, non-cash benefit for Opzelura® (ruxolitinib) cream related to the CMS settlement,* grew 17% compared to the prior year period
Jakafi®/Jakafi XR™ (ruxolitinib) net sales of $817 million, an increase of 7% compared to the same period in 2025
Opzelura net sales of $450 million, an increase of 173% versus the prior year period; excluding the one-time, non-cash benefit,* Opzelura net sales were $204 million, an increase of 24% versus the prior year period
Hematology and Oncology portfolio net sales of $222 million, an increase of 69%, compared to the second quarter of 2025
Updating 2026 full year financial guidance for total net sales and operating expenses
Ten clinical data readouts, including data from four registrational trials, expected throughout the second half of 2026
Conference Cal...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
